Icatibant Glenmark

Icatibant, the active ingredient in Icatibant Glenmark, is a bradykinin B2 receptor antagonist presented as a sterile solution for injection for subcutaneous administration. It is indicated for the treatment of acute attacks of hereditary angioedema type I and type II, providing rapid symptom relief in affected individuals.

GNH USA supplies Icatibant Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled sourcing and reliable cold‑chain logistics where required. The company adheres to stringent regulatory standards and provides comprehensive documentation for import and distribution.

Icatibant is used to treat hereditary angioedema, a disorder characterized by excessive bradykinin‑mediated swelling.

- Hereditary angioedema type I: reduces swelling and pain during acute attacks. - Hereditary angioedema type II: provides rapid relief of edema in acute episodes. - Hereditary angioedema (all types): controls symptoms of sudden swelling episodes.

Icatibant may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Injection site pain: discomfort at the subcutaneous injection site. - Redness or swelling at injection site: localized inflammatory response. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Airway angioedema: swelling that may compromise breathing. - Severe hypotension: marked drop in blood pressure. - Thrombocytopenia: low platelet count that can increase bleeding risk.

Before using Icatibant, certain safety considerations should be observed.

- Confirm diagnosis: ensure the patient has hereditary angioedema type I or II. - Monitor hypersensitivity: watch for signs of allergic reaction during and after injection. - Use under medical supervision: administration should be directed by a qualified healthcare professional. - Avoid in known hypersensitivity: do not give to patients with documented allergy to icatibant or its excipients. - Pregnancy and lactation: safety is unknown; weigh potential benefits against risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect the bradykinin pathway or hemodynamic stability.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and worsen angioedema. - Concomitant use of other bradykinin B2 antagonists: can lead to unpredictable pharmacodynamic effects.

Moderate Interactions (Monitor Closely): - C1‑esterase inhibitor concentrates: may alter clinical response when used together. - Other prophylactic HAE agents (e.g., androgens): monitor for additive effects on swelling control. - Antihistamines: may mask early signs of an allergic reaction, requiring careful observation.